Close Menu

NEW YORK – Geneos Therapeutics said Wednesday that its personalized vaccine GNOS-PV02 will be used in an upcoming clinical trial for advanced hepatocellular carcinoma patients who have progressed on or are intolerant to first-line treatment with a tyrosine kinase inhibitor.

The vaccine contains patient-specific neoantigen targets that will be identified through tumor sequencing. The company's GT-EPIC platform will be used to develop the personalized DNA-based therapies tailored to each patient's unique tumor mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Aug
24
Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Sep
10
Sponsored by
Genecentric

This webinar, Part 2 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will focus on the development of RNA-based companion diagnostics for oncology.